, Alzheimer's Association, 2009.

, Alzheimer's disease facts and figures, Alzheimers Dement, vol.5, pp.234-270

C. Ballard, S. Gauthier, A. Corbett, C. Brayne, and D. Aarsland, Alzheimer's disease, Lancet, vol.377, pp.1019-1031, 2011.

C. P. Ferri, M. Prince, C. Brayne, H. Brodaty, and L. Fratiglioni, Global prevalence of dementia: a Delphi consensus study, Lancet, vol.366, pp.2112-2117, 2005.

C. Helmer, F. Pasquier, and J. F. Dartigues, , 2006.

, Med Sci, vol.22, pp.288-296

H. Hampel, K. Broich, Y. Hoessler, and J. Pantel, Biological markers for early detection and pharmacological treatment of Alzheimer's disease, Dialogues Clin Neurosci, vol.11, pp.141-157, 2009.

O. V. Forlenza, B. S. Diniz, and W. F. Gattaz, Diagnosis and biomarkers of predementia in Alzheimer's disease, BMC Med, vol.8, p.89, 2010.

G. M. Mckhann, Changing concepts of Alzheimer disease, JAMA, vol.305, pp.2458-2459, 2011.

M. W. Weiner, P. S. Aisen, C. R. Jack, J. Jagust, W. J. Trojanowski et al., The Alzheimer's disease neuroimaging initiative: progress report and future plans, Alzheimers Dement, vol.6, pp.202-211, 2010.

S. L. Kulasingam, G. P. Samsa, D. A. Zarin, O. T. Rutschmann, and M. B. Patwardhan, When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis, Value Health, vol.6, pp.542-550, 2003.

P. M. Mcmahon, S. S. Araki, P. J. Neumann, G. J. Harris, and G. S. Gazelle, Costeffectiveness of functional imaging tests in the diagnosis of Alzheimer disease, Radiology, vol.217, pp.58-68, 2000.

P. M. Mcmahon, S. S. Araki, E. A. Sandberg, P. J. Neumann, and G. S. Gazelle, Costeffectiveness of PET in the diagnosis of Alzheimer disease, Radiology, vol.228, pp.515-522, 2003.

N. M. Furiak, R. W. Klein, K. Kahle-wrobleski, E. R. Siemers, and E. Sarpong, Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model, BMC Med Inform Decis Mak, vol.10, p.24, 2010.

J. P. Moatti, L. C. Soriano, A. G. Protiere, and C. , The ''Plan Cancer'' in France: an economists' point of view, Bull Cancer, vol.90, pp.1010-1015, 2003.

T. Tan-torres-edjerer, R. Baltussen, T. Adam, R. Hutubessy, and A. Acharya, WHO guide to cost-effectiveness analysis, 2003.

, TreeAge Software I (2009) TreeAge Pro Healthcare

E. Genin, D. Hannequin, D. Wallon, K. Sleegers, and M. Hiltunen, APOE and Alzheimer disease: a major gene with semi-dominant inheritance, Mol Psychiatry, vol.16, pp.903-907, 2011.

P. J. Neumann, R. C. Hermann, K. M. Kuntz, S. S. Araki, and S. B. Duff, Costeffectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease, Neurology, vol.52, pp.1138-1145, 1999.

F. Fagnani, A. Lafuma, M. Pechevis, A. S. Rigaud, and L. Traykov, Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications, Dement Geriatr Cogn Disord, vol.17, pp.5-13, 2004.

C. L. Himes, G. G. Wagner, D. A. Wolf, H. Aykan, and D. D. Dougherty, Nursing home entry in Germany and the United States, J Cross Cult Gerontol, vol.15, pp.99-118, 2000.

. Ined, Age-and sex-specific mortality rates, 2008.

B. Winblad, K. Engedal, H. Soininen, F. Verhey, and G. Waldemar, A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD, Neurology, vol.57, pp.489-495, 2001.

S. L. Rogers, M. R. Farlow, R. S. Doody, R. Mohs, and L. T. Friedhoff, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group, Neurology, vol.50, pp.136-145, 1998.

R. Mcshane, A. Sastre, A. Minakaran, and N. , Memantine for dementia. Cochrane Database Syst Rev, 2006.

B. Reisberg, R. Doody, A. Stoffler, F. Schmitt, and S. Ferris, Memantine in moderate-to-severe Alzheimer's disease, N Engl J Med, vol.348, pp.1333-1341, 2003.

A. Atri, L. W. Shaughnessy, J. J. Locascio, and J. H. Growdon, Long-term course and effectiveness of combination therapy in Alzheimer disease, Alzheimer Dis Assoc Disord, vol.22, pp.209-221, 2008.

V. Drago, C. Babiloni, D. Bartres-faz, A. Caroli, and B. Bosch, Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage, J Alzheimers Dis, vol.26, pp.159-199, 2011.

C. Blum-boisgard and P. Ulmann, Médicaments spécifiques de la maladie d'Alzheimer. Régime Social des Indépendants, pp.1-130, 2007.

J. Bowen, L. Teri, W. Kukull, W. Mccormick, and S. M. Mccurry, Progression to dementia in patients with isolated memory loss, Lancet, vol.349, pp.763-765, 1997.

D. Commenges, P. Joly, L. Letenneur, and J. F. Dartigues, Incidence and mortality of Alzheimer's disease or dementia using an illness-death model, Stat Med, vol.23, pp.199-210, 2004.

M. J. Katz, R. B. Lipton, C. B. Hall, M. E. Zimmerman, and A. E. Sanders, Agespecific and Sex-specific Prevalence and Incidence of Mild Cognitive Impairment, Dementia, and Alzheimer Dementia in Blacks and Whites: A Report From the Einstein Aging Study, Alzheimer Dis Assoc Disord, 2011.

G. J. Harris, R. F. Lewis, A. Satlin, C. D. English, and T. M. Scott, Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine, AJNR Am J Neuroradiol, vol.19, pp.1727-1732, 1998.

E. C. Mormino, J. T. Kluth, C. M. Madison, G. D. Rabinovici, and S. L. Baker, Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects, Brain, vol.132, pp.1310-1323, 2009.

O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, and K. Blennow, Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol, vol.5, pp.228-234, 2006.

M. De and L. Santé, Tarifs conventionnels des consultations de médecins spécialistes, 2009.

M. De and L. Santé, Classification Commune des Actes Médicaux, 2009.

M. De and L. Santé, Nomenclature des actes de biologie médicale, 2009.

V. Dictionnaire and . Paris,

H. Feldman, S. Gauthier, J. Hecker, B. Vellas, and M. Hux, Economic evaluation of donepezil in moderate to severe Alzheimer disease, Neurology, vol.63, pp.644-650, 2004.

A. S. Rigaud, F. Fagnani, C. Bayle, F. Latour, and L. Traykov, Patients with Alzheimer's disease living at home in France: costs and consequences of the disease, J Geriatr Psychiatry Neurol, vol.16, pp.140-145, 2003.

A. F. Elliott, L. D. Burgio, and J. Decoster, Enhancing caregiver health: findings from the resources for enhancing Alzheimer's caregiver health II intervention, J Am Geriatr Soc, vol.58, pp.30-37, 2010.

A. Reimat, Production associative et bénévolat informel : quelle signification e ´conomique pour les activités de production des retraités, Innovations, vol.15, pp.73-98, 2002.

C. Marbot, Travailler pour des particuliers : souvent une activité d'appoint. Insee Références, Les salaires en France, 2008.

F. Bénévolat-;-ifopfrance and . Bénévolat, La situation du bénévolat en France en 2010, 2010.

D. G. Fryback, E. J. Dasbach, R. Klein, B. E. Klein, and N. Dorn, The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors, Med Decis Making, vol.13, pp.89-102, 1993.

M. Gagnon, B. Rive, M. Hux, and C. Guilhaume, Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada, Can J Psychiatry, vol.52, pp.519-526, 2007.

C. Lejeune, M. J. Bismuth, T. Conroy, C. Zanni, and P. Bey, Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer, J Nucl Med, vol.46, pp.2020-2028, 2005.

D. M. Faissol, P. M. Griffin, and J. L. Swann, Bias in Markov models of disease, Math Biosci, vol.220, pp.143-156, 2009.

J. T. Cohen and P. J. Neumann, Decision analytic models for Alzheimer's disease: state of the art and future directions, Alzheimers Dement, vol.4, pp.212-222, 2008.

V. L. Villemagne, K. E. Pike, D. Darby, P. Maruff, and G. Savage, Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease, Neuropsychologia, vol.46, pp.1688-1697, 2008.

A. Forsberg, H. Engler, O. Almkvist, G. Blomquist, and G. Hagman, PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiol Aging, vol.29, pp.1456-1465, 2008.

D. A. Wolk, J. C. Price, J. A. Saxton, B. E. Snitz, and J. A. James, Amyloid imaging in mild cognitive impairment subtypes, Ann Neurol, vol.65, pp.557-568, 2009.

J. P. Reese, P. Hessmann, G. Seeberg, D. Henkel, and P. Hirzmann, Cost and Care of Patients with Alzheimer's Disease: Clinical Predictors in German Health Care Settings, J Alzheimers Dis, 2011.

J. Mauskopf and L. Mucha, A review of the methods used to estimate the cost of Alzheimer's disease in the United States, Am J Alzheimers Dis Other Demen, vol.26, pp.298-309, 2011.

F. Schachter, L. Faure-delanef, F. Guenot, H. Rouger, and P. Froguel, Genetic associations with human longevity at the APOE and ACE loci, Nat Genet, vol.6, pp.29-32, 1994.

R. J. Caselli, D. Walker, L. Sue, M. Sabbagh, and T. Beach, Amyloid load in nondemented brains correlates with APOE e4, Neurosci Lett, vol.473, pp.168-171, 2010.